The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-07

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol

NCT03164512

Cannabidiol Pharmacokinetics

COMPLETED PHASE1

Investigation of the Pharmacokinetic Profile of CBD

NCT05269706

Opioid Use Disorder

COMPLETED PHASE1

Cannabidiol in Opioid Use Disorder and Chronic Pain

NCT04587791

Chronic Pain Opioid Use Disorder

RECRUITING EARLY_PHASE1

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

NCT04059978

Acute Nociceptive Pain Hyperalgesia Allodynia +1 more

COMPLETED NA

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424

Opioid Use Disorder

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of a novel hemp-derived oral cannabinoid product, at various doses, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design. Drug administration will be double blind (the participant and research staff will be unaware of the dose administered). Upon enrollment, participants will complete 4 dosing conditions (placebo, 1 mg/kg, 2 mg/kg, 4 mg/kg of cannabinoids). Each condition will consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute pharmacodynamic and pharmacokinetic (PK) drug effects. Biological specimens (blood and urine) will be obtained throughout these 8 hours to characterize the pharmacokinetics of CBD, CBD-A, delta-9-Tetrahydrocannabinol (THC), and THC-A, as well as other relevant cannabinoids and metabolites. Pharmacodynamic assessments including subjective drug effects, cognitive performance testing, and vital signs will also be collected for 8 hours post-drug administration. For each of the two days after each experimental session, participants will be asked to return to the lab for brief visits (\~20 min) to provide additional biospecimens (\~24 and \~48 hrs after dosing) to allow for further PK analysis. These procedures will be completed 4 separate times by each participant (sessions will be separated by at least 1 week to allow for sufficient drug washout between doses).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

All participants will complete all dose conditions (study arms) in a randomized order

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Double-blind (Participant, Outcomes Assessor), placebo controlled

Intervention Type DRUG

Participants will ingest soft gel tablets containing placebo for CBD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CBD 1mg/Kg

Participants will ingest soft gel tablets containing CBD 1mg/Kg

Intervention Type DRUG

CBD 2mg/Kg

Participants will ingest soft gel tablets containing CBD 2mg/Kg

Intervention Type DRUG

CBD 4mg/Kg

Participants will ingest soft gel tablets containing CBD 4mg/Kg

Intervention Type DRUG

Placebo CBD

Participants will ingest soft gel tablets containing placebo for CBD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have provided written informed consent
2. Be between the ages of 18 and 55
3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
4. Test negative for recent cannabis use in urine at the screening visit and again upon admission for each experimental session
5. Test negative for other drugs of abuse, including alcohol, at the screening visit and upon arrival for the experimental session
6. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission
7. Weigh between 110 lbs (50 kg) and 220 lbs (100 kg)
8. Blood pressure at screening visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
9. Self-report prior experience using cannabis or CBD products, but no cannabis, cannabinoid, or hemp product use in the prior 30 days
10. Have not donated blood in the prior 30 days
11. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last drug administration session

Exclusion Criteria

1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the past 30 days
2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures
3. Use of an over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant
4. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes.
5. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)
6. Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing
7. Epilepsy or a history of seizures.
8. Individuals with anemia for whom, in the opinion of the study team, participation would pose increased medical risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes